Due to the complex nature of molecule discovery and development, this phase in the workflow is widely acknowledged as one of the most financially risky endeavors for the pharmaceutical industry. Much of this risk comes from failures, which account for 75 percent of the total cost of research and development costs.

Malvern Panalytical's high throughput screening tools enable compound library integrity management, enabling scientists to make better decisions at every step, resulting in a more cost-effective, efficient and predictive molecule discovery process.

In addition, our X-ray powder diffractometers enable the identification or 'fingerprinting' of crystalline phases, as used in the identification of new chemical entities (NCEs) during drug discovery. Crystallographically indexed XRPD patterns directly relate to the crystalline structure of a material and are of critical importance in securing a patent.